Dec 16, 2013
Diffusion MRI and Novel Texture Analysis in Osteosarcoma Xenotransplants Predicts Response to Anti-Checkpoint Therapy
P. Foroutan, J. M. Kreahling, D. L. Morse, O. Grove, M. C. Lloyd, D. Reed, M. Raghavan, S. Altiok, G. V. Martinez, R. J. Gillies , PLoS ONE , DOI: 10.1371/journal.pone.0082875
Combinations of targeted drugs have been employed to treat sarcomas, however, response rates have not improved notably, therefore emphasizing the need for novel treatments. In addition, imaging approaches to assess therapeutic response is lacking, as currently measurable indices, such as volume and/or diameter, do not accurately correlate with changes in...
Dec 16, 2013
TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer
S. Busch, A. Acar, Y. Magnusson, P. Gregersson, L. Rydén, G. Landberg , Oncogene , DOI: 10.1038/onc.2013.527
Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine with the capability to act as tumour suppressor or tumour promoter depending on the cellular context. TGF-beta receptor type-2 (TGFBR2) is the ligand-binding receptor for all members of the TGF-β family. Data from mouse model experiments demonstrated that loss of Tgfbr2 expression...
Dec 15, 2013
Increased risk of hormone therapy failure in breast cancers expressing low phospho-Stat5: Validation of quantitative immunofluorescence assay parameters
M. A. Girondo, A. R. Peck, B. Freydin, I. Chervoneva, T. Hyslop, A. J. Kovatich, J. A. Hooke, C. D. Shriver, E. P. Mitchell, H. Rui , Cancer Research , DOI: 10.1158/0008-5472.SABCS13-P1-08-20
Previous analyses of three breast cancer cohorts revealed that loss of phospho-Stat5 in breast cancer is associated with significantly elevated risk of hormone therapy failure (1, 2). Nuclear localized tyrosine phosphorylated Stat5 (Nuc-pYStat5) may therefore have clinical value as a predictive marker. Analysis of two of the three previously reported...
Dec 15, 2013
Comparison of Ki67 counted by digital pathology image analysis software application and scores determined by pathologists
N. Niikura, N. Kumaki, S. Masuda, T. Xiaoyan, M. Miyazawa, T. Iwamoto, T. Okamura, Y. Saito and Y. Tokuda , Cancer Research , DOI: 10.1158/0008-5472.SABCS13-P3-05-11
Background: Immunohistochemical assessment of the Ki67 has been described as a prognostic and predictive marker for breast cancer. The international panel of experts recommends the counting of as many as 500 or 1000 cancer cells including those in hot spots, which in a routine clinical setting, will be time consuming...
Dec 5, 2013
Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
J. S. Riley, R. Hutchinson, D. G. McArt, N. Crawford, C. Holohan, I. Paul, S. Van Schaeybroeck, M. Salto-Tellez, P. G. Johnston, D. A. Fennell, K. Gately, K. O'Byrne, R. Cummins, E. Kay, P. Hamilton, I. Stasik, D. B. Longley , Cell Death & Disease , DOI: 10.1038/cddis.2013.481
Non-small cell lung carcinoma remains by far the leading cause of cancer-related deaths worldwide. Overexpression of FLIP, which blocks the extrinsic apoptotic pathway by inhibiting caspase-8 activation, has been identified in various cancers. We investigated FLIP and procaspase-8 expression in NSCLC and the effect of HDAC inhibitors on FLIP expression,...